Trimazosin
Chemical compound
- C02CA03 (WHO)
- (2-Hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate
- 35795-16-5
Y - HCl: 53746-46-6 Y
- 37264
- 34203
N
- 31L760807H
- HCl: 827T79ILE7 Y
- D08212 N
- ChEMBL513301 N
- DTXSID50189319
- Interactive image
- O=C(OCC(O)(C)C)N3CCN(c1nc(N)c2c(n1)c(OC)c(OC)c(OC)c2)CC3
InChI
- InChI=1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23)N
- Key:YNZXWQJZEDLQEG-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Trimazosin is a sympatholytic alpha-1 blocker.[1][2]
References
- ^ van Kalken CK, van der Meulen J, Oe PL, Vriesendorp R, Donker AJ (1986). "Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension". Eur. J. Clin. Pharmacol. 31 (1): 63–8. doi:10.1007/BF00870988. PMID 3780829. S2CID 19123951.
- ^ U.S. patent 3,669,968
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
| Central |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peripheral |
|
| Serotonin receptor antagonists | |
|---|---|
| Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
